Natixis Advisors LLC Acquires Shares of 11,245 Medpace Holdings, Inc. (NASDAQ:MEDP)

Natixis Advisors LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,245 shares of the company's stock, valued at approximately $3,754,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Signaturefd LLC raised its stake in Medpace by 4.9% in the 2nd quarter. Signaturefd LLC now owns 559 shares of the company's stock worth $230,000 after purchasing an additional 26 shares in the last quarter. Wealth Alliance grew its position in Medpace by 2.9% during the second quarter. Wealth Alliance now owns 970 shares of the company's stock worth $399,000 after buying an additional 27 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in Medpace by 0.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company's stock worth $1,787,000 after acquiring an additional 32 shares during the period. Nations Financial Group Inc. IA ADV raised its holdings in Medpace by 1.7% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company's stock valued at $793,000 after acquiring an additional 39 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC lifted its position in shares of Medpace by 0.8% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 5,476 shares of the company's stock valued at $1,828,000 after acquiring an additional 41 shares during the period. 77.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent analyst reports. William Blair restated an "outperform" rating on shares of Medpace in a research report on Tuesday, October 22nd. Jefferies Financial Group downgraded shares of Medpace from a "buy" rating to a "hold" rating and lowered their price target for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. TD Cowen cut their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. UBS Group lowered Medpace from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, Truist Financial dropped their price target on shares of Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $380.00.

Medpace Price Performance

Shares of MEDP stock traded down $4.07 on Friday, reaching $337.75. 351,391 shares of the company were exchanged, compared to its average volume of 390,956. The company has a 50-day moving average of $340.14 and a 200-day moving average of $373.13. Medpace Holdings, Inc. has a one year low of $268.80 and a one year high of $459.77. The company has a market cap of $10.50 billion, a price-to-earnings ratio of 29.58, a PEG ratio of 1.89 and a beta of 1.37.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. During the same quarter in the previous year, the company posted $2.22 earnings per share. The company's quarterly revenue was up 8.3% on a year-over-year basis. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.